CN1143117A - Detecting method for Leber hereditary optic nurve pathologic change and its kit - Google Patents

Detecting method for Leber hereditary optic nurve pathologic change and its kit Download PDF

Info

Publication number
CN1143117A
CN1143117A CN 96116296 CN96116296A CN1143117A CN 1143117 A CN1143117 A CN 1143117A CN 96116296 CN96116296 CN 96116296 CN 96116296 A CN96116296 A CN 96116296A CN 1143117 A CN1143117 A CN 1143117A
Authority
CN
China
Prior art keywords
microlitres
add
microlitre
hereditary optic
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 96116296
Other languages
Chinese (zh)
Inventor
周海林
邹祝英
胡育新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Military Medical University SMMU
Original Assignee
Second Military Medical University SMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Military Medical University SMMU filed Critical Second Military Medical University SMMU
Priority to CN 96116296 priority Critical patent/CN1143117A/en
Publication of CN1143117A publication Critical patent/CN1143117A/en
Pending legal-status Critical Current

Links

Abstract

Based on the feature that the patient has point mutation of chondriosome, which results in the loss of restriction enzyme SfaNI recognition site in nomal chondriosome DNA, the present invention detects the said disease according to that the PCR cloning product of specific anticoagulant, hemolysis liquid and one pair of primers can't be digected and cut by restriction enzyme SfaNI. The present invention provides diagnosis method and reagent kit for the clear detection of Leber's hereditary optic hurve pathologic change.

Description

Leber hereditary optic neuropathy detection method and test kit thereof
The present invention relates to the physianthropy health field, is a kind of method and test kit thereof of the Leber of detection hereditary optic neuropathy.
Leber hereditary optic neuropathy is a kind of much illness in eye of matrilinear inheritance.Be everlasting pubescence morbidity, the male sex sees that it is impaired mainly to show as optic nerve more, promptly eyes successively or occur the rapid decline of central vision simultaneously present optic atrophy after the several months.Clinical symptom that this is sick and eyeground performance and acute retrobulbar neuritis, papillitis are very alike, therefore normal clinically easily mistaken diagnosis.(see: 1. " the four example reports of LeberShi disease one family " Chinese ophthalmology disease magazine was rolled up for the 2nd phase in 1993 the 9th for the main dependence familial inheritance history of clarifying a diagnosis clinically; 2. " LeberShi leber's disease " practical ophthalmology magazine was rolled up o. 11th in 1991 the 9th), but some patient is difficult to get the familial inheritance history, China carries out Population control at present in addition, and great majority are the only-child, and the familial inheritance history is difficult for appearing.Up to the present, yet there are no the method for casting aside the familial inheritance history and detecting Leber hereditary optic neuropathy.
The objective of the invention is to provides a kind of method and test kit thereof that need not rely on the familial inheritance history just can detect Leber hereditary optic neuropathy for clinical.
The present inventor finds that according to domestic and international and own to the result of this disease from molecule genetics research in recent years there is mitochondrial point mutation in the patient of Leber hereditary optic neuropathy.Because the existence of plastosome point mutation, make the recognition site forfeiture of the restriction enzyme SfaNI of human high conservative in the normal mtdna.And then, make plastosome production capacity decrease in efficiency, cause cellular oxidation and respiratory dysfunction, especially make the anterior optic nerve unmyelinated nerve fiber that is subject to the influence of plastosome production capacity most, the aixs cylinder of optic ganglion cell, because of the cell energy supply is not enough to keep their complete structure and function, degeneration takes place at last change.Mitochondrial point mutation is regarded as pathogenic relevant with this disease, utilizes PCR method to detect mitochondrial point mutation, just can reach and clearly detect this sick purpose.
Method and this test kit of use of detection Leber hereditary optic neuropathy provided by the invention, be in taking 1 milliliter of venous blood of patient, add specific antithrombotics, extract total DNA (comprising Mitochondrial DNA) through degeneration methods, with the mtDNA fragment of PCR method amplifying specific, again with the cutting of SfaNI restriction enzyme.The normal people, product through pcr amplification can be cut by the SfaNI restriction enzyme, and Leber hereditary optic neuropathy patient, its PGR amplified production then can not be cut by the SfaNI restriction enzyme, can find mitochondrial point mutation from the recognition site forfeiture of restriction enzyme SfaNI, thereby can clearly detect this disease.
Below further set forth concrete preparation of the present invention and operation steps.
The reagent of Leber hereditary optic neuropathy detection kit of the present invention and hemolysate preparation or production unit:
1, specific antithrombotics:
EDTANa 2g
NaCl 0.85g
Add water to the dissolving of 100ml room temperature, 1 milliliter of venous blood of the specific antithrombotics anti-freezing of per 100 microlitres.
2, a pair of primer: by Shanghai plant physiology institute or Shanghai finished product that biochemical research provides.
5 ' AGCCCTCGTAGTAACAGCCA-3 ' light chain POS.11641~11660, every microlitre 500 nanograms.
5 ' GGAGTATAGGGCTGTGACTA-3 ' heavy chain POS.11980~11961, every microlitre 500 nanograms.
3, PCR reagent:
The dNTP200 nanogram(ng)
10 * Buffer, 5 microlitres
TaqDNA polymerase 1.2 units
4, restriction enzyme SfaNI (New England Biolabs product)
NEBuffer3 (New England Biolabs product)
5, hemolysate: Tris-Hcl 10mmol/L PH7.5 NaCl 10mmol/L, MgCl 25mmol/L.
The composition of Leber hereditary optic nerve detection kit of the present invention
1, specific antithrombotics one is managed
2, each pipe of a pair of primer
3, dNTP one pipe
4, TaqDNA polymerase one pipe
5,10 * Buffer, one pipe
6, restriction enzyme SfaNI one pipe
7, NEBuffer3 one pipe
8, hemolysate one pipe
Concrete operation method of the present invention is as follows;
Extract 1 milliliter of patient's peripheric venous blood, add in specific antithrombotics 100 microlitres, become anticoagulation behind the mixing gently, get anticoagulation 50 microlitres again and place 400 microlitre hemolysates mixing gently, left standstill 5 minutes, abandon supernatant through 4000rpm after centrifugal 5 minutes, add 100 microlitre physiological saline mixings, put 100 ℃ of boiling water 7 minutes, 4000rpm of short duration centrifugal (being no more than 1 minute), get supernatant 10 microlitres and make each 20pmol of a pair of primer of template (i.e. 0.2 micrograms of DNA) adding, the dNTP200 nanogram(ng), 10 * Buffer, 5 microlitres add distilled water to 50 microlitre again, putting into the PCR thermal cycler increases: 95 ℃ of sex change 4 minutes, treat to take out when the temperature follow procedure is reduced to 70 ℃ automatically, add TaqDNA polymerase 1.2 units, continue then with 94 ℃ of sex change 40 seconds, 55 ℃ of renaturation 40 seconds, 70 ℃ are extended 30 seconds is a circulation, totally 30 circulations, last 72 ℃ are continued to extend 7 minutes.Learn from else's experience DNA fragment specific 20 microlitres behind the pcr amplification, put in 37 ℃ of water baths digestion 6 hours with 1 unit of SfaNI restriction endonuclease, 2.3 microlitre NEBuffer3, get 10 microlitres and add analysis under the 2% ethidium bromide electrophoresis apparatus, normal person presents two fragments of 190bp, 150bp, and Leber hereditary optic neuropathy patient only presents fragment of 340bp because of its DNA can not be cut by the SfaNI restriction enzyme.
The invention has the beneficial effects as follows to have solved and to lean on the familial inheritance history to diagnose the problem of Leber hereditary optic neuropathy in the past, for the clinical Leber hereditary optic neuropathy that clearly detects provides easy, a reliable method and test kit.

Claims (2)

1, a kind of test kit of clinical detection Leber hereditary optic neuropathy, it is characterized in that forming, be specially by antithrombotics, hemolysate, a pair of primer, dNTP, TaqDNA polymerase, 10 * Buffer, SfaNI restriction enzyme, each pipe of NEBuffer3:
(1.1) specific antithrombotics
EDTANa 2 2g
NaCl 0.85g
Add water to 100ml
(1.2) each pipe of a pair of primer
5 ' AGCCCTCGTAGTAACAGCCA-3 ' light chain POS.11641~11660, every microlitre 500 nanograms.
5GGAGTATAGGGCTGTGACTA-3 ' heavy chain POS.11980~11961, every microlitre 500 nanograms.
(1.3)dNTP
DNTP 200 nanogram(ng)s;
(1.4) TaqDNA polymerase;
TaqDNA polymerase 1.2 units:
(1.5)10×Buffer
10 * Buffer, 5 microlitres;
(1.6) SfaNI restriction enzyme
SfaNI (New England Biolabs product)
(1.7)NEBuffer3
NEBuffer3 (New England Biolabs product) '
(1.8) hemolysate:
Tris-Hcl?10mmol/L.pH7.5
NaCl 10mmol/L,
MgCl 2 5mmol/L。
2, a kind of method of clinical detection Leber hereditary optic neuropathy is characterized in that in turn including the following steps:
(2.1) extract 1 milliliter of patient's peripheric venous blood, add in specific antithrombotics 100 microlitres, shake up gently, become anticoagulation;
(2.2) get anticoagulation 50 microlitres and place 400 microlitre hemolysates to shake up gently, left standstill 5 minutes, abandon supernatant after centrifugal 5 minutes through 4000rpm, add 100 microlitre physiological saline mixings, put 100 ℃ of boiling water 7 minutes, 4000rpm is of short duration centrifugal, gets supernatant 10 microlitres and makes template;
(2.3) add each 20pmol of a pair of primer in template 10 microlitres, the dNTP200 nanogram(ng), 10xBuffer 5 microlitres, add distilled water to 50 microlitre again, put in the PCR thermal cycler and circulate: 95 ℃ of sex change 4 minutes, treat to take out when the temperature follow procedure is reduced to 70 ℃ automatically, add TaqDNA polymerase 1.2 units, continuing then to extend 30 seconds for 40 seconds, 70 ℃ with 94 ℃ of sex change 40 seconds, 55 ℃ of renaturation is a circulation, totally 30 circulations, last 72 ℃ are continued to extend 7 minutes, become the DNA fragment specific behind pcr amplification;
(2.4) learn from else's experience DNA fragment specific 20 microlitres behind the pcr amplification were put in 37 ℃ of water baths digestion 6 hours with 1 unit of SfaNI restriction endonuclease and 2.3 microlitre NEBuffer3;
(2.5) get last resultant 10 microlitres in the step (2.4), add 2% ethidium bromide, analyze under electrophoresis apparatus, normal person presents two fragments of 190dp, 150dp, and Leber hereditary optic neuropathy patient only presents fragment of 340dp.
CN 96116296 1996-04-01 1996-04-01 Detecting method for Leber hereditary optic nurve pathologic change and its kit Pending CN1143117A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 96116296 CN1143117A (en) 1996-04-01 1996-04-01 Detecting method for Leber hereditary optic nurve pathologic change and its kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 96116296 CN1143117A (en) 1996-04-01 1996-04-01 Detecting method for Leber hereditary optic nurve pathologic change and its kit

Publications (1)

Publication Number Publication Date
CN1143117A true CN1143117A (en) 1997-02-19

Family

ID=5123413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 96116296 Pending CN1143117A (en) 1996-04-01 1996-04-01 Detecting method for Leber hereditary optic nurve pathologic change and its kit

Country Status (1)

Country Link
CN (1) CN1143117A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100348732C (en) * 2004-06-15 2007-11-14 中山大学中山眼科中心 Quantitative detection of Leber's genetic optic nerve disease
CN100458419C (en) * 2005-04-26 2009-02-04 浙江大学 Mitochondria DNA11778 point mutation detecting method and reagent case thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100348732C (en) * 2004-06-15 2007-11-14 中山大学中山眼科中心 Quantitative detection of Leber's genetic optic nerve disease
CN100458419C (en) * 2005-04-26 2009-02-04 浙江大学 Mitochondria DNA11778 point mutation detecting method and reagent case thereof

Similar Documents

Publication Publication Date Title
Rigling et al. Reduction of laccase activity in dsRNA-containing hypovirulent strains of Cryphonectria (Endothia) parasitica
Bohle et al. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis
Bowden et al. Serum trypsin-inhibitory activity in five species of farmed fish
Keavney et al. UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM
CN109527270A (en) Leech specific nutrient induces the extracting method of liquid and natural hirudin
EP0457370B1 (en) Method for the pasteurization of the tissue protein PP4
EP0270561B1 (en) Medicaments for the prevention and treatment of alcoholic toxicomania and methods for obtaining them
US9539271B2 (en) Application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of drug for prevention and treatment of thromboembolic diseases
CN1143117A (en) Detecting method for Leber hereditary optic nurve pathologic change and its kit
CN1178693C (en) Prepn for earthworm antibacterial peptide
CN101820891B (en) BCG polysaccharide nucleic acid extractive and preparation method thereof
CN1038512C (en) Medicine for improving growth of liver cell and its method for production
CN1611511A (en) Bacillus subtilis antibacterial peptide separating and purifying method
McManus Examination of neutrophil function in a rat model of decreased host resistance following burn trauma
Brandtzaeg et al. Endotoxin and meningococcemia. Intravascular inflammation induced by native endotoxin in man
WO2000039290A2 (en) Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid
JP2003520043A (en) Composition for detecting β-1,3-glucan, method for producing the same, and kit for detecting β-1,3-glucan using the same
CN1884571A (en) Process for extracting polysaccharide from lycoris plant
CN101538561A (en) Method for extracting CEL I nuclease in celery
YAGO et al. Study on pruritus in hemodialysis patients and the antipruritic effect of neurotropin: plasma levels of C3a, C5a, bradykinin and lipid peroxides
CN111812256A (en) Method for judging fermentation processing end point of gardenia-connected alum solution
NL2031295B1 (en) Preparation method of pea protein tetrapeptide and its application in antihypertensive fields
Hasan et al. Partial purification of topoisomerase IB from serum of diabetic patients and study it's kinetic properties and molecular weight
Fujita et al. Lack of association between the heparan sulfate proteoglycan gene polymorphism and diabetic nephropathy in Japanese NIDDM with proliferative diabetic retinopathy
Sharma et al. Effect of Dictyocaulus filaria infection on the osmotic fragility of sheep erythrocytes

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication